510 related articles for article (PubMed ID: 19643983)
1. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
2. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
[TBL] [Abstract][Full Text] [Related]
3. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
Lozanski G; Heerema NA; Flinn IW; Smith L; Harbison J; Webb J; Moran M; Lucas M; Lin T; Hackbarth ML; Proffitt JH; Lucas D; Grever MR; Byrd JC
Blood; 2004 May; 103(9):3278-81. PubMed ID: 14726385
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
8. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.
Mohr J; Helfrich H; Fuge M; Eldering E; Bühler A; Winkler D; Volden M; Kater AP; Mertens D; Te Raa D; Döhner H; Stilgenbauer S; Zenz T
Blood; 2011 Feb; 117(5):1622-32. PubMed ID: 21115975
[TBL] [Abstract][Full Text] [Related]
9. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.
Zenz T; Mohr J; Edelmann J; Sarno A; Hoth P; Heuberger M; Helfrich H; Mertens D; Dohner H; Stilgenbauer S
Leuk Lymphoma; 2009 Mar; 50(3):510-3. PubMed ID: 19347737
[TBL] [Abstract][Full Text] [Related]
10. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
Fabbri M; Bottoni A; Shimizu M; Spizzo R; Nicoloso MS; Rossi S; Barbarotto E; Cimmino A; Adair B; Wojcik SE; Valeri N; Calore F; Sampath D; Fanini F; Vannini I; Musuraca G; Dell'Aquila M; Alder H; Davuluri RV; Rassenti LZ; Negrini M; Nakamura T; Amadori D; Kay NE; Rai KR; Keating MJ; Kipps TJ; Calin GA; Croce CM
JAMA; 2011 Jan; 305(1):59-67. PubMed ID: 21205967
[TBL] [Abstract][Full Text] [Related]
11. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
12. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
[TBL] [Abstract][Full Text] [Related]
13. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
14. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
Sciumè M; Vincenti D; Reda G; Orofino N; Cassin R; Giannarelli D; Gaidano G; Rossi D; Cortelezzi A
Am J Hematol; 2015 Nov; 90(11):970-4. PubMed ID: 26201283
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
[TBL] [Abstract][Full Text] [Related]
16. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
Zenz T; Benner A; Döhner H; Stilgenbauer S
Cell Cycle; 2008 Dec; 7(24):3810-4. PubMed ID: 19098429
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Lin K; Adamson J; Johnson GG; Carter A; Oates M; Wade R; Richards S; Gonzalez D; Matutes E; Dearden C; Oscier DG; Catovsky D; Pettitt AR
Clin Cancer Res; 2012 Aug; 18(15):4191-200. PubMed ID: 22675167
[TBL] [Abstract][Full Text] [Related]
20. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.
Yu L; Kim HT; Kasar S; Benien P; Du W; Hoang K; Aw A; Tesar B; Improgo R; Fernandes S; Radhakrishnan S; Klitgaard J; Lee C; Getz G; Setlur SR; Brown JR
Clin Cancer Res; 2017 Feb; 23(3):735-745. PubMed ID: 27503198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
